Annex Advisory Services LLC Acquires 3,059 Shares of Abbott Laboratories $ABT

Key Points

• Annex Advisory Services LLC increased its holdings in Abbott Laboratories by 4.2% during Q2, acquiring an additional 3,059 shares and bringing its total ownership to 76,006 shares, valued at approximately $10.34 million.
• Abbott Laboratories reported Q2 earnings per share of $1.26, meeting analysts' expectations, with a revenue of $11.14 billion, surpassing projections of $11.01 billion.
• The company recently announced a quarterly dividend of $0.59 per share, scheduled for payment on November 17, representing an annualized yield of 1.7%.

Annex Advisory Services LLC raised its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 4.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 76,006 shares of the healthcare product maker's stock after purchasing an additional 3,059 shares during the period. Annex Advisory Services LLC's holdings in Abbott Laboratories were worth $10,338,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Farther Finance Advisors LLC raised its stake in Abbott Laboratories by 19.7% in the second quarter. Farther Finance Advisors LLC now owns 39,491 shares of the healthcare product maker's stock worth $5,371,000 after buying an additional 6,486 shares in the last quarter. Silver Oak Securities Incorporated raised its position in shares of Abbott Laboratories by 4.1% in the 2nd quarter. Silver Oak Securities Incorporated now owns 7,253 shares of the healthcare product maker's stock worth $986,000 after acquiring an additional 284 shares in the last quarter. UMB Bank n.a. lifted its stake in shares of Abbott Laboratories by 1.6% during the 2nd quarter. UMB Bank n.a. now owns 312,757 shares of the healthcare product maker's stock worth $42,538,000 after purchasing an additional 4,854 shares during the last quarter. WealthBridge Investment Counsel Inc. boosted its position in Abbott Laboratories by 1.8% during the second quarter. WealthBridge Investment Counsel Inc. now owns 65,793 shares of the healthcare product maker's stock valued at $8,949,000 after purchasing an additional 1,150 shares in the last quarter. Finally, Shelton Wealth Management LLC grew its stake in Abbott Laboratories by 379.1% in the second quarter. Shelton Wealth Management LLC now owns 9,544 shares of the healthcare product maker's stock valued at $1,298,000 after purchasing an additional 7,552 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Trading Up 1.2%

Abbott Laboratories stock opened at $136.22 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.30 and a debt-to-equity ratio of 0.25. The firm has a market cap of $237.09 billion, a PE ratio of 17.07, a P/E/G ratio of 2.58 and a beta of 0.69. The stock's 50 day simple moving average is $130.47 and its two-hundred day simple moving average is $131.14. Abbott Laboratories has a 12 month low of $110.86 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion during the quarter, compared to analysts' expectations of $11.01 billion. During the same period in the previous year, the business posted $1.14 EPS. The business's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.7%. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have commented on ABT. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating for the company in a research report on Friday, July 18th. Evercore ISI raised their target price on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Tuesday, July 8th. Leerink Partnrs raised Abbott Laboratories to a "hold" rating in a research report on Monday, June 16th. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Finally, Raymond James Financial dropped their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $145.22.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.